Nephros (NASDAQ:NEPH) Rating Increased to Buy at Zacks Investment Research

Nephros (NASDAQ:NEPHGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a report released on Wednesday, reports. The firm presently has a $5.25 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 15.38% from the company’s previous close.

According to Zacks, “Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. “

Separately, B. Riley dropped their price target on shares of Nephros from $11.25 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, February 16th.

Shares of NEPH stock opened at $4.55 on Wednesday. Nephros has a 12 month low of $3.77 and a 12 month high of $11.67. The company has a market cap of $46.92 million, a PE ratio of -11.10 and a beta of 1.24. The company has a current ratio of 5.70, a quick ratio of 3.70 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $4.43.

Nephros (NASDAQ:NEPHGet Rating) last announced its earnings results on Wednesday, February 23rd. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.01). Nephros had a negative net margin of 37.74% and a negative return on equity of 25.91%. The business had revenue of $2.77 million for the quarter, compared to the consensus estimate of $2.81 million. During the same quarter last year, the firm posted ($0.08) EPS. Equities research analysts expect that Nephros will post -0.38 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in NEPH. Cowen Prime Advisors LLC boosted its stake in Nephros by 5.4% in the 3rd quarter. Cowen Prime Advisors LLC now owns 660,150 shares of the company’s stock worth $5,790,000 after purchasing an additional 33,700 shares in the last quarter. Morgan Stanley raised its position in Nephros by 186.3% in the 3rd quarter. Morgan Stanley now owns 13,837 shares of the company’s stock worth $121,000 after buying an additional 9,004 shares during the last quarter. Elkhorn Partners Limited Partnership raised its position in Nephros by 78.8% in the 4th quarter. Elkhorn Partners Limited Partnership now owns 15,200 shares of the company’s stock worth $90,000 after buying an additional 6,700 shares during the last quarter. Finally, Wexford Capital LP purchased a new position in Nephros in the 4th quarter worth about $646,532,000. Institutional investors own 15.14% of the company’s stock.

Nephros Company Profile (Get Rating)

Nephros, Inc develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Featured Stories

Get a free copy of the Zacks research report on Nephros (NEPH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with's FREE daily email newsletter.